Miguel Abboud to Hydroxyurea
This is a "connection" page, showing publications Miguel Abboud has written about Hydroxyurea.
Connection Strength
1.863
-
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020 04 06; 4:CD012389.
Score: 0.665
-
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017 05 13; 5:CD012389.
Score: 0.544
-
Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis. Am J Hematol. 2008 Oct; 83(10):818-20.
Score: 0.299
-
Sickle cell disease. Lancet. 2017 07 15; 390(10091):311-323.
Score: 0.133
-
Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering. Pediatr Blood Cancer. 2010 Mar; 54(3):398-402.
Score: 0.083
-
Chemical and functional analysis of generic hydroxyurea formulations. Pediatr Hematol Oncol. 2008 Jun; 25(5):423-9.
Score: 0.073
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
Score: 0.039
-
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov; 88(11):E255-60.
Score: 0.026